Arcoma (ARCOMA.ST) Stock Analysis & AI Equity Report
Arcoma (ARCOMA.ST) overview
Arcoma (ARCOMA.ST) stock analysis and AI equity research. For the latest completed financial year, 2024, Arcoma reported revenue of SEK 157m and operating profit of SEK 13.7m; the year-end share price was 10.75 SEK and market capitalisation was SEK 142m. Arcoma is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Arcoma's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-18. Data will be refreshed during report generation.
About Arcoma
Arcoma AB develops, produces and supplies complete digital radiography and radiology solutions, including X-ray systems, detectors and accessories for hospitals and clinics. The company manufactures in Sweden and sells through OEM partners and distributors internationally. Its products are used across general radiology and specialized applications, with emphasis on workflow, ergonomics and patient comfort.
Generate the Arcoma report
Arcoma is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Arcoma and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.